Claims for Patent: 5,945,033

Summary for Patent: 5,945,033

Title:	Method for making non-crosslinked protein particles for therapeutic and diagnostic use
Abstract:	Albumin particles in the nanometer and micrometer size range in an aqueous suspension are rendered stable against resolubilization without the aid of a crosslinking agent and without denaturation, by the incorporation of hemoglobin in the particle composition. Particles which are primarily hemoglobin in the nanometer and micrometer size range in an aqueous suspension are rendered stable against aggregation by the incorporation of either albumin, surface active agents or gelatin.
Inventor(s):	Yen; Richard C. K. (Glendora, CA)
Assignee:	Hemosphere, Inc. (Irvine, CA)
Application Number:	08/747,137
Patent Claims:	1. A method for the preparation of an aqueous suspension of monodisperse particles of non-crosslinked, non-denatured albumin, having a size range of from about 50 to about 5000 nanometers in diameter and stable against dissolving upon dilution with an alcohol-free aqueous dilution medium, said method comprising: (a) forming an aqueous solution containing albumin and hemoglobin; and (b) treating said aqueous solution with an alcohol in an amount sufficient to cause said aqueous solution to become turbid; wherein steps (a) and (b) are performed without crosslinking said albumin and hemoglobin. 2. A method in accordance with claim 1 in which said hemoglobin of step (a) is from about 1% to about 70% by weight relative to the total of said albumin and said hemoglobin. 3. A method in accordance with claim 1 in which said hemoglobin of step (a) is from about 1% to about 30% by weight relative to the total of said albumin and said hemoglobin. 4. A method in accordance with claim 1 in which said alcohol is a lower alkyl alcohol. 5. A method in accordance with claim 1 in which said alcohol is a member selected from the group consisting of methanol, ethanol, n-propanol, isopropanol and n-butanol. 6. A method in accordance with claim 1 in which said alcohol is a member selected from the group consisting of ethanol and n-butanol. 7. A method in accordance with claim 1 in which step (a) further comprises including in said aqueous solution an anionic water-soluble surfactant. 8. A method in accordance with claim 7 in which said anionic water-soluble surfactant is included at a concentration of at least about 0.1 g per liter of said suspension. 9. A method in accordance with claim 7 in which said anionic water-soluble surfactant is included at a concentration of from about 0.5 g to about 5 g per liter of said suspension, and said particles comprise at least about 15 g per liter of said suspension. 10. A method in accordance with claim 7 in which said anionic water-soluble surfactant is a member selected from the group consisting of sodium lauryl sulfate and sodium tetradecylsulfate, and is included at a concentration of from about 0.5 g to about 5 g per liter of said suspension, and said particles comprise at least about 15 g per liter of said suspension. 11. A method in accordance with claim 1 in which said hemoglobin is human hemoglobin. 12. A method in accordance with claim 1 in which said albumin is human serum albumin.

Details for Patent 5,945,033

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942		2011-01-15
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954		2011-01-15
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976		2011-01-15
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978		2011-01-15
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	02/17/1995		2011-01-15
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	06/11/2003		2011-01-15
Csl Behring Llc	ALBUMINAR, ALBUMINAR-20, ALBUMINAR-25, ALBUMINAR-5	albumin (human)	Injection	103955	03/17/2000		2011-01-15